Ocular Therapeutix's (OCUL) probability of success for its Axpaxli drug in wet age-related macular degeneration, or wAMD, is still 75%, UBS analysts said in a Monday note. The not ...
You wake up one morning, open your stock chart, and find that a stock you hold has jumped by 50%. Or, without any warning, it ...
Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)’s zibotentan succeeds in ...
Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click ...
"I changed jobs and my annual income went up by 1 million yen." If you look at social media, stories like this are everywhere ...
An analysis of 31 years of World Series data reveals which games matter most, how victories affect championship odds, and what mathematics says about winning.
A trio of superstars are battling it out for this year's prestigious Ballon d'Or, all three of whom have never won before.
Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced ...
A new quantum algorithm speeds up optimization problems by leveraging localisation–delocalisation transitions, potentially ...
The English champions almost exist as a counter to the individual qualities the Ballon d'Or glorifies. Arsenal won the league ...
The industry is on the cusp of a transformative wave, as a series of intensive, high-impact catalysts converge to reshape its ...
Madrigal Pharmaceuticals (ISIN US5588681057) has an analyst target of USD 735.00 after UBS raised it from USD 669.00 on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results